Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

Gene Therapy
Assaf C BesterBatsheva Kerem

Abstract

Following gene therapy of SCID-X1 using murine leukemia virus (MLV) derived vector, two patients developed leukemia owing to an activating vector integration near the LMO2 gene. We found that these integrations reside within FRA11E, a common fragile site known to correlate with chromosomal breakpoints in tumors. Further analysis showed that fragile sites attract a nonrandom number of MLV integrations, shedding light on its integration mechanism and risk-to-benefit ratio in gene therapy.

References

Apr 28, 2000·Science·M Cavazzana-CalvoA Fischer
Sep 28, 2002·Blood·Manfred SchmidtChristof von Kalle
Mar 15, 2003·Cancer Letters·Nicholas C Popescu
Aug 18, 2004·PLoS Biology·Rick S MitchellFrederic D Bushman
Mar 12, 2005·Science·Jocelyn Kaiser

❮ Previous
Next ❯

Citations

Nov 30, 2007·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·C BaumA Thrasher
Jan 19, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Luca BiascoAlessandro Aiuti
Aug 29, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Reba CondiottiEithan Galun
Jan 11, 2013·Nature Reviews. Cancer·Jacqueline M MatthewsDavid J Curtis
Jan 25, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Charlotte DalbaDavid Klatzmann
Jun 10, 2008·Current Opinion in Hematology·Robert SokolicFabio Candotti
Aug 3, 2007·The Journal of Clinical Investigation·Alessandro AiutiClaudio Bordignon
Jun 21, 2014·Human Gene Therapy·Christof von KalleManfred Schmidt
Jul 14, 2012·Chromosoma·Nazario Bosco, Titia de Lange
Sep 23, 2014·Cellular and Molecular Life Sciences : CMLS·Alexandros G GeorgakilasVassilis G Gorgoulis
Oct 10, 2014·Cellular and Molecular Life Sciences : CMLS·Efrat Ozeri-GalaiBatsheva Kerem
Sep 19, 2014·Cellular and Molecular Life Sciences : CMLS·Larissa Savelyeva, Lena M Brueckner
Jun 4, 2008·Upsala Journal of Medical Sciences·Fredrik Johansson Swartling
Apr 3, 2012·Trends in Genetics : TIG·Efrat Ozeri-GalaiBatsheva Kerem
Apr 9, 2008·Journal of Cellular Biochemistry·Flavia PichiorriKay Huebner
Oct 26, 2006·Genes, Chromosomes & Cancer·Anne FechterManfred Schwab
Aug 3, 2007·Genes, Chromosomes & Cancer·Małgorzata SawińskaLarissa Savelyeva
Dec 13, 2006·Clinical & Developmental Immunology·Arvind KumarM Eric Gershwin
Nov 18, 2005·Blood·Noboru MitsuhashiMary Kearns-Jonker
Feb 10, 2007·International Journal of Cancer. Journal International Du Cancer·Anne FechterLarissa Savelyeva
Oct 24, 2018·International Journal of Molecular Sciences·Wei-Chung Tsao, Kristin A Eckert
Aug 23, 2021·Biomedical Engineering Online·Saša Haberl Meglič, Mojca Pavlin
Jul 14, 2010·Advanced Drug Delivery Reviews·Qizhen Shi, Robert R Montgomery

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.